MEDIQON Group AG (CHG) AI Stock Analysis

• Market Cap: €629.43M
• Dividend Yield: N/A
• Average Volume (3M): 26.38K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.25
• Revenue Growth: 51.05%
• EPS Growth: -242.58%
• Country: DE
• Employees: 800
• Sector: Technology
• Sector Strength: 88
• Industry: Information Technology Services
• EPS (TTM): -0.69
• Shares Outstanding: 23,842,152
• 10 Day Avg. Volume: 27,625
• 30 Day Avg. Volume: 26,381
• PEG Ratio: -0.40
• Price to Book (P/B): 2.59
• Price to Sales (P/S): 5.28
• P/FCF Ratio: 83.86
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.5
• Revenue Forecast (FY): €237.05M

• Rating: 45 Neutral
• Price Target: €40.00 ▼(-1.48% Downside)
• Action: Reiterated Date: 11/01/25
• Date: Action: Reiterated 11/01/25

The overall stock score for MEDIQON Group AG is primarily influenced by its financial performance, which shows strong revenue growth but significant profitability challenges. Technical analysis indicates a lack of strong momentum, while valuation is negatively impacted by the company's unprofitability and lack of dividend yield. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Revenue Growth

Sustained revenue expansion indicates growing market adoption of MEDIQON's devices and software. Durable top-line growth supports scale, improves leverage on fixed costs, and creates optionality for reinvesting in product R&D and commercial expansion over the next several quarters.

Diversified Revenue Streams

A multi‑stream business model (hardware, recurring software licenses, and partnerships) reduces single-product risk and smooths revenue volatility. Recurring licensing and partner channels bolster long-term customer retention and provide structural stability to cash flows.

Improving Cash Generation and Leverage

Evidence of positive free cash flow growth and improved leverage suggests growing internal funding capacity. Stronger cash generation and lower reliance on debt enhance financial flexibility to fund product development, partnerships, or working capital needs over multiple quarters.

Negative Factors

Unprofitability and Negative Margins

Persisting negative net income and EBIT margins show the company is not yet converting sales into profit. This structural profitability shortfall constrains retained earnings, limits reinvestment, and may require ongoing external capital if not remedied within the medium term.

Negative Return on Equity

A negative ROE signals that shareholder capital has not generated positive returns, undermining long‑term investor value creation. Continued negative ROE can hinder the company's ability to raise equity and raises scrutiny on capital allocation and operational efficiency.

Gross Margin Deterioration

A notable decline in gross margin points to structural cost or pricing pressure in core products. Even with revenue growth, persistent margin erosion jeopardizes path to profitability and reduces the payoff from operating leverage as the business scales.

MEDIQON Group AG Business Overview & Revenue Model

Company Description

CHAPTERS Group AG, together with its subsidiaries, provides software solutions in the DACH region. It also provides building cleaning and related services; electronic gate and door systems, as well as barriers, fire, and smoke protection systems; CAD/CAM software solutions; conversation-oriented language courses; communication design degree; pest control services; software solutions to sheet metal processing, property management, property developers, and project development industries, as well as engages in planning, consultation, and construction in the field of refrigeration and air conditioning technology, and air purification. In addition, the company provides software solutions for managing fire brigades, as well as mountain, water, and cave rescues; winKITA software; software for utilities and heating bills for private landlords and property managers; industry solutions for property developers; supplemental alarming solutions for fire brigades, rescue services, and emergency organizations; and corporate and group planning, and business intelligence solutions. Further, it offers enterprise content management software solutions; business management solutions for builders and project developers; solutions for property management companies; orchestra management software; modular software solutions; school administration software; ERP software; broadband networks for municipal utilities, municipalities, and other network owners; technical solutions; and support services for international students and young professionals, as well as imports and distributes cable protection products. Additionally, the company develops and sells software solution for fishing, hunting, and gun license administration; and provides CRM software solution to electricity and gas suppliers, water and energy suppliers, and public service broadcasters. The company was formerly known as MEDIQON Group AG and changed its name to CHAPTERS Group AG in July 2023. CHAPTERS Group AG was founded in 1998 and is based in Hamburg, Germany.

How the Company Makes Money

MEDIQON Group AG generates revenue through multiple streams, primarily from the sale of medical devices and technology solutions to healthcare providers, hospitals, and clinics. The company also earns income from licensing its proprietary software solutions, which facilitate efficient health data management and patient interaction. Additionally, MEDIQON has established strategic partnerships with other healthcare organizations and technology firms, allowing for collaborative product development and expanded market reach. These partnerships enhance the company's service offerings, driving further revenue through joint ventures and shared technology initiatives.

MEDIQON Group AG Financial Statement Overview

Summary

MEDIQON Group AG is experiencing strong revenue growth, but profitability remains a concern with negative net income and EBIT margins. The balance sheet shows improved leverage, but profitability metrics like ROE are still negative. Cash flow generation is improving, but further analysis is needed to understand cash flow efficiency fully.

Income Statement

MEDIQON Group AG has shown strong revenue growth of 27.02% in the latest year, indicating a positive trajectory. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin has decreased significantly from the previous year, suggesting potential challenges in cost management or pricing strategy.

Balance Sheet

The company's debt-to-equity ratio has improved over the years, indicating better leverage management. However, the return on equity remains negative, reflecting ongoing challenges in generating profits from shareholders' equity. The equity ratio is stable, suggesting a balanced capital structure.

Cash Flow

MEDIQON Group AG has achieved positive free cash flow growth, which is a positive sign for liquidity. However, the operating cash flow to net income ratio is not available, limiting insights into cash flow efficiency. The free cash flow to net income ratio is also unavailable, which could provide further clarity on cash generation relative to earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2021	Dec 2021	Dec 2020
Income Statement
Total Revenue	131.62M	110.67M	70.77M	42.07M	28.66M	1.08M
Gross Profit	-2.22M	47.02M	8.38M	6.84M	12.26M	360.69K
EBITDA	1.59M	16.35M	16.14M	4.82M	7.16M	-1.33M
Net Income	-23.07M	-11.47M	-4.08M	-5.88M	-2.27M	-2.27M
Balance Sheet
Total Assets	591.39M	353.74M	223.95M	169.28M	103.55M	49.81M
Cash, Cash Equivalents and Short-Term Investments	52.20M	58.51M	50.84M	26.28M	11.09M	614.04K
Total Debt	200.34M	73.60M	69.35M	62.09M	51.70M	25.00M
Total Liabilities	306.36M	128.75M	99.87M	77.11M	61.71M	41.55M
Stockholders Equity	224.81M	224.99M	126.06M	93.76M	42.57M	10.00M
Cash Flow
Free Cash Flow	10.70M	6.96M	3.81M	3.67M	1.15M	-1.76M
Operating Cash Flow	13.38M	11.47M	7.37M	5.69M	2.87M	-1.76M
Investing Cash Flow	-147.02M	-98.82M	-36.34M	-53.21M	-47.40M	-5.21M
Financing Cash Flow	135.34M	89.00M	48.15M	58.78M	47.06M	7.22M

MEDIQON Group AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 40.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:CHG, the sentiment is Negative. The current price of 40.6 is above the 20-day moving average (MA) of 30.62, above the 50-day MA of 36.13, and above the 200-day MA of 39.03, indicating a bearish trend. The MACD of -2.87 indicates Positive momentum. The RSI at 25.43 is Positive, neither overbought nor oversold. The STOCH value of 12.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:CHG.

MEDIQON Group AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GFT	69 Neutral	€368.56M	10.53	13.78%	2.65%	3.28%	-26.16%
NA9	68 Neutral	€737.86M	15.08	24.22%	1.29%	5.63%	-7.19%
COK	65 Neutral	€726.43M	42.03	3.09%	3.78%	-0.61%	-52.28%
D6H	62 Neutral	€597.33M	27.10	13.54%	1.43%	7.30%	-15.88%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
ADN1	56 Neutral	€375.37M	27.65	6.82%	0.85%	12.37%	196.11%
CHG	45 Neutral	€629.43M	-27.58	-12.43%	―	51.05%	-242.58%